<DOC>
	<DOC>NCT00151918</DOC>
	<brief_summary>The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride</brief_summary>
	<brief_title>Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Patients receiving haemodialysis for ESRD Patients must have received haemodialysis for chronic renal failure three times per week for at least the previous 2 months Pregnant or lactating women Patients with clinically significant uncontrolled concurrent illness, a lifethreatening malignancy or current multiple myeloma Patients who are HIV+ Patients with any significant bowel obstruction, active inflammatory bowel disease, GI motility disorders, or a history of major GI surgery within the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>